Rivastigmine Actavis 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
amended 
on 
IB/0032 
C.I.2.a - Change in the SPC, Labelling or PL of a 
07/02/2024 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
IG/1612 
A.1 - Administrative change - Change in the name 
31/05/2023 
and/or address of the MAH 
SmPC, 
Labelling and 
PL 
IAIN/0030 
A.5.a - Administrative change - Change in the name 
09/05/2022 
05/05/2023 
Annex II and 
and/or address of a manufacturer/importer 
responsible for batch release 
PL 
IA/0029/G 
This was an application for a group of variations. 
04/04/2022 
n/a 
B.III.1.b.2 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
New certificate for a starting 
material/reagent/intermediate/or excipient from a 
new or an already approved manufacturer 
B.III.1.b.4 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
Deletion of certificates (in case multiple certificates 
exist per material) 
B.III.1.b.3 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
Updated certificate from an already approved 
manufacturer 
B.III.1.b.3 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
Updated certificate from an already approved 
manufacturer 
IB/0028 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
15/03/2022 
07/06/2022 
SmPC, 
life of the finished product - As packaged for sale 
Labelling and 
(supported by real time data) 
Page 2/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IA/0027 
A.7 - Administrative change - Deletion of 
09/04/2021 
07/06/2022 
Annex II and 
manufacturing sites 
PL 
PL 
IA/0026 
B.III.1.a.2 - Submission of a new/updated or 
08/07/2020 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
IB/0025 
B.I.b.2.e - Change in test procedure for AS or 
02/07/2019 
n/a 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
IA/0024/G 
This was an application for a group of variations. 
21/06/2019 
n/a 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
Page 3/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
B.III.1.b.2 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
New certificate for a starting 
material/reagent/intermediate/or excipient from a 
new or an already approved manufacturer 
B.III.1.b.2 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
New certificate for a starting 
material/reagent/intermediate/or excipient from a 
new or an already approved manufacturer 
B.III.1.b.2 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
New certificate for a starting 
material/reagent/intermediate/or excipient from a 
new or an already approved manufacturer 
B.III.1.b.4 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
Deletion of certificates (in case multiple certificates 
exist per material) 
B.III.2.z - Change to comply with Ph. Eur. or with a 
national pharmacopoeia of a Member State - Other 
variation 
N/0023 
Minor change in labelling or package leaflet not 
04/04/2018 
07/06/2022 
PL 
connected with the SPC (Art. 61.3 Notification) 
N/0022 
Minor change in labelling or package leaflet not 
24/07/2017 
07/06/2022 
Labelling and 
connected with the SPC (Art. 61.3 Notification) 
PL 
Page 4/12 
 
 
 
 
 
 
 
 
 
 
IB/0020/G 
This was an application for a group of variations. 
06/01/2017 
n/a 
B.II.b.1.e - Replacement or addition of a 
manufacturing site for the FP - Site where any 
manufacturing operation(s) take place, except batch-
release, batch control, primary and secondary 
packaging, for non-sterile medicinal products 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
B.II.b.3.a - Change in the manufacturing process of 
the finished or intermediate product - Minor change 
in the manufacturing process 
IA/0021 
B.II.d.2.a - Change in test procedure for the finished 
05/01/2017 
n/a 
product - Minor changes to an approved test 
procedure 
IAIN/0019/G 
This was an application for a group of variations. 
25/04/2016 
16/02/2017 
Annex II and 
PL 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.1.b - Replacement or addition of a 
manufacturing site for the FP - Primary packaging 
site 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Page 5/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Not including batch control/testing 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
IAIN/0018/G 
This was an application for a group of variations. 
17/02/2016 
16/02/2017 
Annex II and 
PL 
A.7 - Administrative change - Deletion of 
manufacturing sites 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.1.b - Replacement or addition of a 
manufacturing site for the FP - Primary packaging 
site 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
R/0016 
Renewal of the marketing authorisation. 
17/12/2015 
15/02/2016 
Annex II and 
Labelling 
IB/0017 
C.I.2.a - Change in the SPC, Labelling or PL of a 
07/12/2015 
15/02/2016 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Page 6/12 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0015/G 
This was an application for a group of variations. 
04/09/2015 
15/02/2016 
SmPC, Annex 
II, Labelling 
and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
Page 7/12 
 
 
 
 
 
 
 
 
new additional data is required to be submitted by 
the MAH 
IB/0013/G 
This was an application for a group of variations. 
03/06/2015 
15/02/2016 
SmPC, Annex 
C.I.7.a - Deletion of - a pharmaceutical form 
C.I.7.b - Deletion of - a strength 
II, Labelling 
and PL 
IB/0014/G 
This was an application for a group of variations. 
22/05/2015 
n/a 
B.III.1.a.1 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - New certificate from 
an already approved manufacturer 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
B.I.b.1.z - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Other variation 
IAIN/0012/G 
This was an application for a group of variations. 
26/03/2015 
n/a 
A.7 - Administrative change - Deletion of 
manufacturing sites 
C.I.8.a - Introduction of or changes to a summary of 
Pharmacovigilance system - Changes in QPPV 
(including contact details) and/or changes in the 
PSMF location 
Page 8/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N/0011 
Minor change in labelling or package leaflet not 
12/08/2014 
15/02/2016 
PL 
connected with the SPC (Art. 61.3 Notification) 
N/0010 
Minor change in labelling or package leaflet not 
15/01/2014 
15/02/2016 
PL 
Update of details for local representatives in Annex IIIB. 
connected with the SPC (Art. 61.3 Notification) 
N/0009 
Minor change in labelling or package leaflet not 
16/08/2013 
15/02/2016 
PL 
Exchanging a graphic in the product information leaflet. 
connected with the SPC (Art. 61.3 Notification) 
II/0008 
To add an alternative manufacturer of the active 
27/06/2013 
n/a 
substance (rivastigmine hydrogen tartrate) for 
manufacture of Rivastigmine capsules. 
B.I.a.1.b - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Introduction of a new manufacturer of the AS that is 
supported by an ASMF 
X/0005 
Line extension (addition of  new pharmaceutical form 
21/02/2013 
17/04/2013 
SmPC, Annex 
The MAH applied for the addition of a new pharmaceutical 
/new route of administration). Transdermal Patches 
II, Labelling 
form / new route of administration. Transdermal patches 
of 4.6 mg/24 hours and 9.5 mg/24 hours. 
and PL 
have been developed as generic products to Exelon 
Annex I_2.(d) Change or addition of a new 
pharmaceutical form 
transdermal patches (4.6 mg/24 hours and 9.5 mg/24 
hours). The composition per unit area is identical for both 
strengths. 
The manufacturing process has been described and critical 
steps identified. Information on development, manufacture 
and control of this new pharmaceutical form has been 
presented. The product development has been described 
and several in vitro and in vivo proofs of concept clinical 
studies have been performed before the final composition 
was chosen and tested in a bioequivalence study. The in 
Page 9/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0007 
C.I.2.a - Change in the SPC, Labelling or PL of a 
11/07/2012 
n/a 
SmPC and PL 
Update of SmPC and PL in line with updates of the 
vitro method chosen for the control of the drug substance 
prove similarity between the two strengths. Data has been 
provided showing that the method is discriminatory. The 
applicant has also presented data to ensure adhesion 
equivalence between the two dosage strengths. 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
originator’s product Exelon/Prometax (WS-132) adopted on 
16 March 2012.  
Update of section 4.8 of the SmPC to reflect the safety 
findings of the open-label safety study in patients with 
Parkinson’s disease dementia. Additionally, sections 4.3 
and 4.4 were updated with information on skin application 
site reactions and skin hypersensitivity, recommendations 
on formulation switching and treatment discontinuation. 
The Package Leaflet was updated in accordance. Minor 
editorial changes were introduced throughout the Product 
Information. 
IB/0006/G 
This was an application for a group of variations. 
12/03/2012 
25/05/2012 
SmPC and PL 
To update the SmPC and PL in line with updates of the 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
originator’s product Exelon/Prometax introduced in the 
work sharing procedures WS-119 and WS-121-G, which 
were adopted by the CHMP on 14 April 2011. The EMA 
variation request EMA/360627/2011 was dated 10 January 
2012. 
C.I.2a) WS-119 included the following updates: 
Update of sections 4.3 and 4.4 of Exelon/Prometax oral 
formulations SmPC to change the contraindication for 
patients with severe hepatic impairment into a warning, in 
accordance with Exelon/Prometax transdermal patch SmPC. 
Section 4.4 of the SmPC for the oral formulations is also 
revised to reflect that patients with clinically significant 
Page 10/12 
 
 
 
 
 
 
 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
renal or hepatic impairment might experience more 
adverse reactions. Section 4.2 is amended accordingly. In 
addition, minor linguistic amendments have been 
introduced in the SmPC in line with the reference medicinal 
product. 
The Package Leaflet has been amended to reflect those 
changes. 
Finally, the Package Leaflet of all Rivastigmine Actavis 
presentations is revised based on the results of a 
Exelon/Prometax user testing (FUM 026). 
C.I.2a) WS-121-G included the following updates: 
Following a request from the CHMP (PSUR 18) and a safety 
review analysis from the MAH, section 4.8 of the SmPC has 
been amended to include new adverse reactions: 
dehydration, hepatitis, aggression, restlessness and sick 
sinus syndromes. In addition, anxiety has been included in 
section 4.8 of the Rivastigmine Actavis SmPCs in line with 
the reference medicinal product. The whole section 4.8 has 
been revised according to the current MedDRA terminology 
in line with the reference medicinal product. 
Section 4.4 of the SmPC for all formulations has also been 
amended to include that gastrointestinal disorders may 
occur in patients treated with rivastigmine. 
The Package Leaflet has been amended to reflect those 
changes. 
C.I.2a) WS-121-G included additional updates: 
Finally, section 4.4 of the oral formulations SmPC has been 
revised to include a warning for patients with low body 
weight. 
The Package Leaflet has been amended to reflect those 
changes. 
Additionally, contact information for Czech Republic and 
Page 11/12 
 
 
 
 
 
 
Cyprus has been updated in sections 6 of the Package 
Leaflets. 
IB/0004 
B.I.b.2.e - Change in test procedure for AS or 
12/01/2012 
n/a 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
IB/0003 
B.II.b.3.z - Change in the manufacturing process of 
12/01/2012 
n/a 
the finished product - Other variation 
IB/0001/G 
This was an application for a group of variations. 
16/11/2011 
25/05/2012 
SmPC, 
B.II.f.1.d - Stability of FP - Change in storage 
conditions of the finished product or the 
diluted/reconstituted product 
B.II.a.1.a - Change or addition of imprints, bossing 
or other markings including replacement, or addition 
of inks used for product marking - Changes in 
imprints, bossing or other markings 
Labelling and 
PL 
Page 12/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
